Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study

Abstract Background According to the NAPOLI-1 trial, nanoliposomal irinotecan (nal-IRI) plus fluorouracil/folinic acid (5-FU/LV) showed improved overall survival compared to fluorouracil alone for patients with metastatic pancreatic cancer who were previously treated with gemcitabine-based therapy....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Se Jun Park, Hyunho Kim, Kabsoo Shin, Tae Ho Hong, Ja Hee Suh, Myung Ah Lee
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Pancreatic cancer Liposomal irinotecan Gemcitabine-refractory Second-line treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/4925642ab4544182841d608bafad7bf1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4925642ab4544182841d608bafad7bf1
record_format	dspace
spelling	oai:doaj.org-article:4925642ab4544182841d608bafad7bf12021-11-08T11:01:59ZNanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study10.1186/s12885-021-08887-11471-2407https://doaj.org/article/4925642ab4544182841d608bafad7bf12021-11-01T00:00:00Zhttps://doi.org/10.1186/s12885-021-08887-1https://doaj.org/toc/1471-2407Abstract Background According to the NAPOLI-1 trial, nanoliposomal irinotecan (nal-IRI) plus fluorouracil/folinic acid (5-FU/LV) showed improved overall survival compared to fluorouracil alone for patients with metastatic pancreatic cancer who were previously treated with gemcitabine-based therapy. In that trial, Asian patients had frequent dose modification due to haematological toxicity. There has been limited information on the clinical benefits and toxicity of this regimen in real-world settings. In this study, we assessed real-world experience of nal-IRI plus 5-FU/LV in patients with advanced pancreatic cancer after gemcitabine failure. Methods We conducted a single institution, retrospective analysis of response, survival and safety in patients who had been treated with nal-IRI with 5-FU/LV. Patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy received nal-IRI (80 mg/m2) with 5-FU/LV every 2 weeks. Kaplan-Meier analysis was performed to obtain median progression free survival and median overall survival. The hazard ratio and 95% confidence interval (CI) were estimated using a stratified Cox regression model. A multivariate Cox proportional hazards regression model was used to identify the effects of clinical factors. Results Fifty-one patients received nal-IRI plus 5-FU/LV between January 2015 and December 2020. The median age was 67 years, and males were 58.8%. A total of 40 (78.4%) and 11 (21.6%) patients had received one and two lines of prior chemotherapy before enrollment, respectively. Median progression-free survival was 2.8 months (95% CI 1.8–3.7) and median overall survival was 7.0 months (95% CI 6.0–7.9). Chemotherapy doses were reduced or delayed in 33 (64.7%) patients during the first 6 weeks and median relative dose intensity was 0.87. Thirty-six (70.6%) patients experienced grade 3 or 4 adverse events, most commonly neutropenia (58.8%). Most non-haematologic adverse events were under grade 2. Since the start of first-line chemotherapy, median overall survival was 16.3 months (95% CI 14.1–18.4). Conclusions Nal-IRI plus 5-FU/LV seems to be effective, with manageable toxicities, following gemcitabine-based treatment in patients with metastatic pancreatic ductal adenocarcinoma. Nal-IRI plus 5-FU/LV following gemcitabine with nab-paclitaxel is a feasible sequential treatment option in patients with metastatic pancreatic cancer. Trial registration Retrospectively registered.Se Jun ParkHyunho KimKabsoo ShinTae Ho HongJa Hee SuhMyung Ah LeeBMCarticlePancreatic cancerLiposomal irinotecanGemcitabine-refractorySecond-line treatmentNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Pancreatic cancer Liposomal irinotecan Gemcitabine-refractory Second-line treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Pancreatic cancer Liposomal irinotecan Gemcitabine-refractory Second-line treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Se Jun Park Hyunho Kim Kabsoo Shin Tae Ho Hong Ja Hee Suh Myung Ah Lee Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
description	Abstract Background According to the NAPOLI-1 trial, nanoliposomal irinotecan (nal-IRI) plus fluorouracil/folinic acid (5-FU/LV) showed improved overall survival compared to fluorouracil alone for patients with metastatic pancreatic cancer who were previously treated with gemcitabine-based therapy. In that trial, Asian patients had frequent dose modification due to haematological toxicity. There has been limited information on the clinical benefits and toxicity of this regimen in real-world settings. In this study, we assessed real-world experience of nal-IRI plus 5-FU/LV in patients with advanced pancreatic cancer after gemcitabine failure. Methods We conducted a single institution, retrospective analysis of response, survival and safety in patients who had been treated with nal-IRI with 5-FU/LV. Patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy received nal-IRI (80 mg/m2) with 5-FU/LV every 2 weeks. Kaplan-Meier analysis was performed to obtain median progression free survival and median overall survival. The hazard ratio and 95% confidence interval (CI) were estimated using a stratified Cox regression model. A multivariate Cox proportional hazards regression model was used to identify the effects of clinical factors. Results Fifty-one patients received nal-IRI plus 5-FU/LV between January 2015 and December 2020. The median age was 67 years, and males were 58.8%. A total of 40 (78.4%) and 11 (21.6%) patients had received one and two lines of prior chemotherapy before enrollment, respectively. Median progression-free survival was 2.8 months (95% CI 1.8–3.7) and median overall survival was 7.0 months (95% CI 6.0–7.9). Chemotherapy doses were reduced or delayed in 33 (64.7%) patients during the first 6 weeks and median relative dose intensity was 0.87. Thirty-six (70.6%) patients experienced grade 3 or 4 adverse events, most commonly neutropenia (58.8%). Most non-haematologic adverse events were under grade 2. Since the start of first-line chemotherapy, median overall survival was 16.3 months (95% CI 14.1–18.4). Conclusions Nal-IRI plus 5-FU/LV seems to be effective, with manageable toxicities, following gemcitabine-based treatment in patients with metastatic pancreatic ductal adenocarcinoma. Nal-IRI plus 5-FU/LV following gemcitabine with nab-paclitaxel is a feasible sequential treatment option in patients with metastatic pancreatic cancer. Trial registration Retrospectively registered.
format	article
author	Se Jun Park Hyunho Kim Kabsoo Shin Tae Ho Hong Ja Hee Suh Myung Ah Lee
author_facet	Se Jun Park Hyunho Kim Kabsoo Shin Tae Ho Hong Ja Hee Suh Myung Ah Lee
author_sort	Se Jun Park
title	Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
title_short	Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
title_full	Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
title_fullStr	Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
title_full_unstemmed	Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
title_sort	nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
publisher	BMC
publishDate	2021
url	https://doaj.org/article/4925642ab4544182841d608bafad7bf1
work_keys_str_mv	AT sejunpark nanoliposomalirinotecanplusfluorouracilandfolinicacidasasecondlinetreatmentoptioninpatientswithmetastaticpancreaticductaladenocarcinomaaretrospectivecohortstudy AT hyunhokim nanoliposomalirinotecanplusfluorouracilandfolinicacidasasecondlinetreatmentoptioninpatientswithmetastaticpancreaticductaladenocarcinomaaretrospectivecohortstudy AT kabsooshin nanoliposomalirinotecanplusfluorouracilandfolinicacidasasecondlinetreatmentoptioninpatientswithmetastaticpancreaticductaladenocarcinomaaretrospectivecohortstudy AT taehohong nanoliposomalirinotecanplusfluorouracilandfolinicacidasasecondlinetreatmentoptioninpatientswithmetastaticpancreaticductaladenocarcinomaaretrospectivecohortstudy AT jaheesuh nanoliposomalirinotecanplusfluorouracilandfolinicacidasasecondlinetreatmentoptioninpatientswithmetastaticpancreaticductaladenocarcinomaaretrospectivecohortstudy AT myungahlee nanoliposomalirinotecanplusfluorouracilandfolinicacidasasecondlinetreatmentoptioninpatientswithmetastaticpancreaticductaladenocarcinomaaretrospectivecohortstudy
_version_	1718442419770359808

Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study

Ejemplares similares